The Role of IL-22 in Cancer

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 Sep 4

PMID 39231878

Authors

Zachary E Hunzeker

Lei Zhao

Austin M Kim

Jacob M Parker

Ziwen Zhu

Huaping Xiao

Qian Bai

Mark R Wakefield

Yujiang Fang

Affiliations

Soon will be listed here.

Abstract

Interleukin-22, discovered in the year of 2000, is a pleiotropic Th17 cytokine from the IL-10 family of cytokines. IL-22 signals through the type 2 cytokine receptor complex IL-22R and predominantly activates STAT3. This pathway leads to the transcription of several different types of genes, giving IL-22 context-specific functions ranging from inducing antimicrobial peptide expression to target cell proliferation. In recent years, it has been shown that IL-22 is involved in the pathogenesis of neoplasia in some cancers through its pro-proliferative and anti-apoptotic effects. This review highlights studies with recent discoveries and conclusions drawn on IL-22 and its involvement and function in various cancers. Such a study may be helpful to better understand the role of IL-22 in cancer so that new treatment could be developed targeting IL-22.

Citing Articles

Construction of a prognostic signature based on T-helper 17 cells differentiation-related genes for predicting survival and tumor microenvironment in head and neck squamous cell carcinoma.

Chen S, Wei P, Wang G, Wu F, Zou J Medicine (Baltimore). 2025; 104(4):e41273.

PMID: 39854737 PMC: 11771614. DOI: 10.1097/MD.0000000000041273.

References

Dudakov J, Hanash A, van den Brink M . Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015; 33:747-85. PMC: 4407497. DOI: 10.1146/annurev-immunol-032414-112123. View

Shuttleworth S, Townsend P, Silva F, Cecil A, Hill T, Tomassi C . Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases. Prog Med Chem. 2011; 50:109-33. DOI: 10.1016/B978-0-12-381290-2.00003-3. View

Ouyang W, Rutz S, Crellin N, Valdez P, Hymowitz S . Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2010; 29:71-109. DOI: 10.1146/annurev-immunol-031210-101312. View

Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa J, Renauld J . Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem. 2002; 277(37):33676-82. DOI: 10.1074/jbc.M204204200. View

Demaria M, Poli V . Pro-malignant properties of STAT3 during chronic inflammation. Oncotarget. 2012; 3(4):359-60. PMC: 3380569. DOI: 10.18632/oncotarget.482. View

Gialeli C, Theocharis A, Karamanos N . Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2010; 278(1):16-27. DOI: 10.1111/j.1742-4658.2010.07919.x. View

Muhl H, Scheiermann P, Bachmann M, Hardle L, Heinrichs A, Pfeilschifter J . IL-22 in tissue-protective therapy. Br J Pharmacol. 2013; 169(4):761-71. PMC: 3687657. DOI: 10.1111/bph.12196. View

Lopez D, Kongsbak-Wismann M . Role of IL-22 in homeostasis and diseases of the skin. APMIS. 2022; 130(6):314-322. PMC: 9324963. DOI: 10.1111/apm.13221. View

Arshad T, Mansur F, Palek R, Manzoor S, Liska V . A Double Edged Sword Role of Interleukin-22 in Wound Healing and Tissue Regeneration. Front Immunol. 2020; 11:2148. PMC: 7527413. DOI: 10.3389/fimmu.2020.02148. View

10.

Perusina Lanfranca M, Lin Y, Fang J, Zou W, Frankel T . Biological and pathological activities of interleukin-22. J Mol Med (Berl). 2016; 94(5):523-34. PMC: 4860114. DOI: 10.1007/s00109-016-1391-6. View

11.

Wang X, Wong K, Ouyang W, Rutz S . Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. Cold Spring Harb Perspect Biol. 2017; 11(2). PMC: 6360861. DOI: 10.1101/cshperspect.a028548. View

12.

Kirchberger S, Royston D, Boulard O, Thornton E, Franchini F, Szabady R . Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013; 210(5):917-31. PMC: 3646494. DOI: 10.1084/jem.20122308. View

13.

Khawar M, Azam F, Sheikh N, Abdul Mujeeb K . How Does Interleukin-22 Mediate Liver Regeneration and Prevent Injury and Fibrosis?. J Immunol Res. 2017; 2016:2148129. PMC: 5168458. DOI: 10.1155/2016/2148129. View

14.

Xie M, Aggarwal S, Ho W, Foster J, Zhang Z, Stinson J . Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem. 2000; 275(40):31335-9. DOI: 10.1074/jbc.M005304200. View

15.

Kotenko S . The family of IL-10-related cytokines and their receptors: related, but to what extent?. Cytokine Growth Factor Rev. 2002; 13(3):223-40. DOI: 10.1016/s1359-6101(02)00012-6. View

16.

Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld J . IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun. 2001; 1(8):488-94. DOI: 10.1038/sj.gene.6363716. View

17.

Bleicher L, de Moura P, Watanabe L, Colau D, Dumoutier L, Renauld J . Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism. FEBS Lett. 2008; 582(20):2985-92. DOI: 10.1016/j.febslet.2008.07.046. View

18.

Brockmann L, Giannou A, Gagliani N, Huber S . Regulation of T17 Cells and Associated Cytokines in Wound Healing, Tissue Regeneration, and Carcinogenesis. Int J Mol Sci. 2017; 18(5). PMC: 5454945. DOI: 10.3390/ijms18051033. View

19.

Huber S, Gagliani N, Zenewicz L, Huber F, Bosurgi L, Hu B . IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 2012; 491(7423):259-63. PMC: 3493690. DOI: 10.1038/nature11535. View

20.

Katara G, Kulshrestha A, Schneiderman S, Riehl V, Ibrahim S, Beaman K . Interleukin-22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer. Mol Oncol. 2019; 14(1):211-224. PMC: 6944104. DOI: 10.1002/1878-0261.12598. View